Figure S2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

Robert J. Lake; Parisa Nikeghbal; Irina V. Lagutina; Kimberly K. Leslie; Mara P. Steinkamp; Hua-Ying Fan

doi:10.1158/2767-9764.30328467

October 10, 2025Open Access

Figure S2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

View Full Paper

Ask AI

Bookmark

Share

Key Points

Combination therapy significantly reduces tumor burden in ovarian cancer models, enhancing treatment effects.
Bioluminescent imaging revealed notable differences in tumor size across treatment groups at week 13.
The analysis was performed using multiple unpaired t-tests to determine statistical significance of outcomes.
Findings support further exploration of auranofin as a therapeutic agent in NOTCH-dependent ovarian cancer.

Implication

Supplementary figure measures tumor burden reduction in NOTCH-dependent ovarian cancer, highlighting efficacy of auranofin and cisplatin combination.

Abstract

Supplementary Figure S2 displays individual bioluminescent tumor burden measurements in OVCAR3 cell–derived xenograft mice at week 13 via IVIS Spectrum; significance was assessed by multiple unpaired t-tests (ns, p > 0.05).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lake et al. (2025) studied this question.

synapsesocial.com/papers/68eb8fe250220ac955d94c05 https://doi.org/10.1158/2767-9764.30328467

View Full Paper

Ask AI

Bookmark

Share

Figure S2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Figure S2 from Auranofin Synergizes with Cisplatin in Reducing Tumor Burden of NOTCH-Dependent Ovarian Cancer

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading